blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1786466

EP1786466 - Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors [Right-click to bookmark this link]
Former [2007/21]COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN ANTAGONIST OF A GENE PRODUCT FOR TREATING TUMORS
[2013/18]
StatusNo opposition filed within time limit
Status updated on  27.06.2014
Database last updated on 11.04.2026
Most recent event   Tooltip08.07.2016Lapse of the patent in a contracting state
New state(s): HU		published on 10.08.2016  [2016/32]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990 / US
[N/P]
Former [2008/38]For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco CA 94080-4990 / US
Former [2007/21]For all designated states
Genentech Inc.
1 DNA Way
South San Francisco, CA 94080 / US
Inventor(s)01 / POLAKIS, Paul
1449 Cortez Avenue
Burlingame, CA 94010 / US
 [2007/21]
Representative(s)Denison, Christopher Marcus, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[N/P]
Former [2013/34]Denison, Christopher Marcus, et al
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS / GB
Former [2007/21]Denison, Christopher Marcus, et al
Mewburn Ellis LLP York House 23 Kingsway
London WC2B 6HP / GB
Application number, filing date05789195.417.06.2005
[2007/21]
WO2005US21378
Priority number, dateUS20040580745P18.06.2004         Original published format: US 580745 P
[2007/21]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006009805
Date:26.01.2006
Language:EN
[2006/04]
Type: A2 Application without search report 
No.:EP1786466
Date:23.05.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 26.01.2006 takes the place of the publication of the European patent application.
[2007/21]
Type: B1 Patent specification 
No.:EP1786466
Date:21.08.2013
Language:EN
[2013/34]
Search report(s)International search report - published on:EP04.01.2007
ClassificationIPC:A61K45/06, A61P35/00, A61K48/00, A61K31/4745, A61K31/513
[2007/21]
CPC:
A61K31/4745 (EP,US); A61K31/513 (EP,US); A61K31/522 (EP,US);
A61K31/525 (EP,US); A61K31/7072 (EP,US); A61K31/7076 (EP,US);
A61K45/06 (EP,US); A61P35/00 (EP); A61P35/04 (EP);
A61P43/00 (EP); C07K16/30 (EP,US); A61K2039/505 (EP,US);
C12N2799/022 (EP,US) (-)
C-Set:
A61K31/4745, A61K2300/00 (EP,US);
A61K31/513, A61K2300/00 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/21]
TitleGerman:Kombination mit einem Chemotherapeutikum und einem Antagonist eines Genprodukts zur Behandlung von Tumoren[2013/18]
English:Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors[2013/18]
French:Combinaison d'un agent chimiothérapeutique avec un antagoniste d'un produit d'un gène pour traitement tumoral[2013/18]
Former [2007/21]KOMBINATION MIT EINEM CHEMOTHERAPEUTIKUM UND EINEM ANTAGONIST EINES GENPRODUKTS ZUR BEHANDLUNG VON TUMOREN
Former [2007/21]COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN ANTAGONIST OF A GENE PRODUCT FOR TREATING TUMORS
Former [2007/21]COMBINAISON D'UN AGENT CHEMIOTHERAPIQUE AVEC UN ANTAGONISTE D'UN PRODUIT DU GENE POUR TRAITEMENT TUMORAL
Entry into regional phase16.01.2007National basic fee paid 
16.01.2007Designation fee(s) paid 
16.01.2007Examination fee paid 
Examination procedure16.01.2007Examination requested  [2007/21]
03.04.2007Amendment by applicant (claims and/or description)
02.12.2008Despatch of a communication from the examining division (Time limit: M06)
29.07.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
24.08.2009Reply to a communication from the examining division
18.01.2011Despatch of a communication from the examining division (Time limit: M04)
27.05.2011Reply to a communication from the examining division
08.04.2013Communication of intention to grant the patent
02.07.2013Fee for grant paid
02.07.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.12.2008
Opposition(s)22.05.2014No opposition filed within time limit [2014/31]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
24.08.2009Request for further processing filed
24.08.2009Full payment received (date of receipt of payment)
Fees paidRenewal fee
16.01.2007Renewal fee patent year 03
28.03.2008Renewal fee patent year 04
16.06.2009Renewal fee patent year 05
11.06.2010Renewal fee patent year 06
13.06.2011Renewal fee patent year 07
24.05.2012Renewal fee patent year 08
31.03.2013Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.06.2005
AT21.08.2013
BE21.08.2013
BG21.08.2013
CY21.08.2013
CZ21.08.2013
DK21.08.2013
EE21.08.2013
FI21.08.2013
LT21.08.2013
MC21.08.2013
NL21.08.2013
PL21.08.2013
RO21.08.2013
SE21.08.2013
SI21.08.2013
SK21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
[2016/32]
Former [2016/25]AT21.08.2013
BE21.08.2013
BG21.08.2013
CY21.08.2013
CZ21.08.2013
DK21.08.2013
EE21.08.2013
FI21.08.2013
LT21.08.2013
MC21.08.2013
NL21.08.2013
PL21.08.2013
RO21.08.2013
SE21.08.2013
SI21.08.2013
SK21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2015/09]AT21.08.2013
BE21.08.2013
CY21.08.2013
CZ21.08.2013
DK21.08.2013
EE21.08.2013
FI21.08.2013
LT21.08.2013
MC21.08.2013
NL21.08.2013
PL21.08.2013
RO21.08.2013
SE21.08.2013
SI21.08.2013
SK21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2014/23]AT21.08.2013
BE21.08.2013
CY21.08.2013
CZ21.08.2013
DK21.08.2013
EE21.08.2013
FI21.08.2013
LT21.08.2013
NL21.08.2013
PL21.08.2013
RO21.08.2013
SE21.08.2013
SI21.08.2013
SK21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2014/22]AT21.08.2013
BE21.08.2013
CY21.08.2013
DK21.08.2013
FI21.08.2013
LT21.08.2013
NL21.08.2013
PL21.08.2013
RO21.08.2013
SE21.08.2013
SI21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2014/21]AT21.08.2013
BE21.08.2013
CY21.08.2013
DK21.08.2013
FI21.08.2013
LT21.08.2013
PL21.08.2013
SE21.08.2013
SI21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2014/18]AT21.08.2013
BE21.08.2013
CY21.08.2013
FI21.08.2013
LT21.08.2013
PL21.08.2013
SE21.08.2013
SI21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2014/14]CY17.07.2013
AT21.08.2013
BE21.08.2013
FI21.08.2013
LT21.08.2013
PL21.08.2013
SE21.08.2013
SI21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2014/12]CY17.07.2013
AT21.08.2013
FI21.08.2013
LT21.08.2013
PL21.08.2013
SE21.08.2013
SI21.08.2013
GR22.11.2013
IS21.12.2013
PT23.12.2013
Former [2014/11]CY17.07.2013
AT21.08.2013
FI21.08.2013
LT21.08.2013
PL21.08.2013
SE21.08.2013
IS21.12.2013
PT23.12.2013
Former [2014/10]CY17.07.2013
AT21.08.2013
LT21.08.2013
SE21.08.2013
IS21.12.2013
PT23.12.2013
Former [2014/09]AT21.08.2013
LT21.08.2013
SE21.08.2013
PT23.12.2013
Former [2014/08]LT21.08.2013
PT23.12.2013
Cited inInternational search[A]   ADLARD J W ET AL: "Prediction of the response of colorectal cancer to systemic therapy", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 3, no. 2, February 2002 (2002-02-01), pages 75 - 82, XP004811698, ISSN: 1470-2045 [A] 1-48 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1470-2045(02)00648-4
Examination  ROTHENBERG M L: "Irenotecan (CPT-11): Recent developments and future directions - Colorectal cancer and beyond", ONCOLOGIST 2001 US, vol. 6, no. 1, 2001, pages 66 - 80, ISSN: 1083-7159
by applicant  GREENLEE ET AL.: "Cancer statistics", CA CANCER J CLIN., vol. 51, 2001, pages 15 - 36
   ADJEI, A.A., CLIN. PHARMACAL., vol. 48, 1999, pages 265 - 277
   POON ET AL., J. CLIN. ONCOL., vol. 9, 1991, pages 1967 - 1972
   RAGNHAMMER ET AL., ACTA ONCOL, vol. 40, 2001, pages 282 - 308
   SALTZ ET AL., N. ENGL. J MED., vol. 343, 2000, pages 905 - 914
   PARKER, BAMES, METHODS IN MOLECULAR BIOLOGY, vol. 106, 1999, pages 247 - 283
   HOD, BIOTECHNIQUES, vol. 13, 1992, pages 852 - 854 [A] 1-48 * the whole document *
   WEIS ET AL., TRENDS IN GENETICS, vol. 8, 1992, pages 263 - 264
   R. EKINS, F.W. CHU, TRENDS ILL BIOTECHNOLOGY, vol. 17, 1999, pages 217 - 218
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.